Acute Myeloid Leukemia Clinical Trial
— BRIDGEOfficial title:
Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia
In relapsed or refractory AML allogeneic HCT is considered to be the only treatment by which
long-term disease-free survival can be achieved. Despite this favorable prospect, even in
younger patients with relapsed AML only about 40% of the patients reach allogeneic HCT. A
number of factors contribute to this low rate of transplantation, among them moderate
activity of the salvage regimens and accumulating toxicities which prevent from
transplantation; Prospective clinical trials in this indication usually focus either on the
rate of CR achieved after a defined number of cycles of salvage therapy or on
transplantation modalities. The consequent integration of salvage therapy into a transplant
strategy accounting for the time-dependent process of donor search has not been studied so
far.
The objective of this study is to evaluate the safety and efficacy of clofarabine salvage
therapy prior to allogeneic HCT.
Status | Completed |
Enrollment | 86 |
Est. completion date | December 2013 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of AML according to WHO criteria. - Untreated relapse or refractory disease after a minimum of one standard induction therapy. Treatment of relapse with leukocyte-apheresis or up to 5 days with low dose cytarabine or hydroxyurea is allowed. - Refractory disease is defined as =5% blasts after the second cycle of induction therapy or no reduction in marrow blasts at early treatment assessment (day +15) after the first cycle of induction therapy. - Relapse is defined as an increase in bone marrow blast count =5%, re-appearance of blasts in the peripheral blood or extramedullary disease. - Age above 40 years. - Have adequate renal and hepatic functions as indicated by the following laboratory values: - Serum creatinine <=1.0 mg/dL; if serum creatinine >1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be >60 mL/min/1.73 m2 (see reference below*) - Serum bilirubin <=1.5× upper limit of normal (ULN) - Aspartate transaminase (AST)/alanine transaminase (ALT) <=2.5× ULN - Alkaline phosphatase <=2.5× ULN - Eligibility for intensive chemotherapy - Patient needs to be capable to understand the clinical trial as an investigational approach to bridge the time to potential allogeneic HCT, potential risks and benefits of the study. - Signed written informed consent. - Female patients of childbearing potential must have a negative serum - Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment. Exclusion Criteria: - For refractory disease, more than two prior induction chemotherapies or more than one prior salvage chemotherapy containing high-dose cytarabine (cumulative dose of cytarabine = 5 g/m2). - Second or higher relapse. Patients who received hypomethylating agents like azacytidine or decitabine as a treatment of first relapse, respond and relapse later on may be included. - Acute promyelocytic leukemia with t(15;17)(q22;q12) molecular detection or (PML/RARa). - Central nervous system involvement (i.e. WBC = 5/µL in cerebrospinal fluid with blasts present on cytospin). - Prior allogeneic HCT - Autologous transplantation within 100 days prior to start of study treatment - Use of investigational agents or anticancer therapy within 10 days before study entry with the exception of hydroxyurea or low-dose cytarabine. - Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo transplantation. - Patients with known refractoriness to platelet support. - Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). - Pregnant or lactating patients. - Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | HELIOS Klinikum Bad Saarow | Bad Saarow | |
Germany | Klinikum Chemnitz gGmbH | Chemnitz | |
Germany | University Hospital Carl Gustav Carus | Dresden | |
Germany | Universitätsklinikum Erlangen | Erlangen | |
Germany | Klinikum der J. W. Goethe-Universität | Frankfurt am Main | |
Germany | Klinikum Mannheim GmbH | Mannheim | |
Germany | Universitätsklinikum Münster | Münster | |
Germany | Klinikum Nürnberg Nord | Nürnberg | |
Germany | Universitätsklinikum Tübingen | Tübingen | |
Germany | Universitätsklinikum Würzburg | Würzburg |
Lead Sponsor | Collaborator |
---|---|
Technische Universität Dresden | Genzyme, a Sanofi Company |
Germany,
Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehning — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of treatment success | Treatment success is defined as a complete remission (CR, CRi or CRchim) at final response assessment after having completed the study treatment. CR and CRi are defined according to standard criteria (ELN). Complete remission by chimerism (CR chim) is defined as a >95% overall donor chimerism assessed by STR-PCR in bone marrow and absence of extramedullary disease together with an absolute neutrophil count >0.5 /nL (500/µL). | To be evaluated 42 days after start of last cycle of chemotherapy containing clofarabine | No |
Secondary | Rate of transplantation | Rate of patients who finally proceeded to allogeneic HCT after bridging therapy with Clofarabine | see evaluation of primary endpoint | No |
Secondary | Adverse drug reactions | Rate of adverse drug reactions. | see evaluation of primary endpoint | Yes |
Secondary | Treatment failure | Cause specific analysis of treatment failure | see evaluation of primary endpoint | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |